Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT04402541
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
55
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Myeloid Leukemia, in Relapse
Myelodysplastic Syndromes
Interventions
DRUG:
CB-5339
Sponsor
Cleave Therapeutics, Inc.